In vitro and in vivo studies have suggested that human complement component C5a plays a key role in neutrophil injury in the adult respiratory distress syndrome (ARDS). First, using leukocyte aggregometry, we demonstrated that the addition of a recently developed rabbit anti-human polyclonal antibody to C5a des arg to endotoxin-activated plasma prevented leukocyte aggregation in vitro. We then administered the anti-C5a des arg antibody to septic primates (Macaca fascicularis). Three groups of primates, control, septic, and anti-C5a antibody treated septic, were studied (n = 4 in each group). A 30-min infusion of Escherichia coli (1 X 10(10)/kg) resulted in severe sepsis and ARDS. Primates were killed 4 h after completion of the E. coli infusion. Septic animals not treated with anti-C5a antibody had 75% mortality (3/4), decreased oxygenation, severe pulmonary edema, and profound hypotension. Septic primates treated with anti-C5a antibodies did not die and did not develop decreased oxygenation (P less than 0.05) or increased extravascular lung water (P less than 0.05). They also had a marked recovery in their mean arterial blood pressure (P less than 0.05). This study demonstrates that treatment with rabbit anti-human C5a des arg antibodies attenuates ARDS and some of the systemic manifestations of sepsis in nonhuman primates.
Introduction
The adult respiratory distress syndrome (ARDS)' is a common and often fatal complication ofseptic shock (1, 2) . Several cellular and humoral factors have been implicated in the pathogenesis of ARDS, including neutrophils, platelets, fibrin, arachidonic acid metabolites, serotonin, histamine, and human complement component C5a (3) . Recent reports have suggested that C5a mediates neutrophil attraction, aggregation, activation, and subsequent pulmonary endothelial damage (4) (5) (6) . This sequence of events may be the primary pathogenetic mechanism for the Receivedfor publication 18 March 1985 and in revisedform 19 February 1986. 1 . Abbreviations used in this paper: ARDS, adult respiratory distress syndrome; CFUJ, colony forming units; EAP, endotoxin activated plasma; EVLW, extravascular lung water; MAP, mean arterial pressure; N/S, normal saline; PAP, pulmonary arterial pressure; PBSG, phosphatebuffered saline with 0.1% glucose; PCWP, pulmonary capillary wedge pressure; SVR, systemic vascular resistance. development of ARDS in septic shock (3) . In vitro studies have demonstrated that C5a generated from endotoxin or zymosanactivated plasma causes neutrophil aggregation (7) . In addition, C5a-activated neutrophils are more adherent and are cytopathic to endothelial cells in tissue culture (8) .
In vivo studies investigating mice which are genetically deficient in CS have established that C5 is required for pulmonary edema formation in response to pneumococcal sepsis, scald wounds, and hyperoxia (9-1 1). When patients at high risk to develop ARDS were followed prospectively, detection of an elevated C5a was a useful predictor of the onset of ARDS (12). The present study was designed to evaluate the effects of a recently developed polyclonal antibody to C5a des arg on the development of ARDS in septic primates.
Methods
Anti-C5a des argpreparation. Immunogen was prepared from zymosanactivated human plasma and gel filtration/ion exchange chromatography according to the method described by Hugli and Chenoweth (13) . The C5a des arg obtained was checked for its purity with cellulose acetate electrophoresis and amino acid analysis and used as the immunogen. New Zealand white rabbits were immunized with the immunogen, and antiserum to human complement C5a des arg was obtained. Cross-reactivity is observed between anti-C5a and the parent C5 molecule but not with C3a, C3, or C4a. Therefore, anti-C5a des arg antibody is highly specific for C5a (13, 14) .
Rabbit anti-human C5a des arg was titrated by radioimmunoassay (Upjohn Diagnostics, The Upjohn Company, Kalamazoo, MI). The titer of the antiserum (percent bound label/total label) used in this experiment was 1:1,200.
Immunoglobulin was prepared from 10 ml of the antiserum with a modified method for horse IgG preparation (15) . The final solution of IgG fraction from the antiserum was made particle-free by centrifugation at 18,000 rpm for 30 min. Concentration of protein was determined with an ultraviolet absorption at 280 nm (energy wavelength 280 nm, 1 mg/ml = 1.5). Nonspecific immunoglobulin from nonimmunized New Zealand white rabbits was prepared as above and was used as sham antibody infusion for animals in groups I and II.
Leukocyte aggregation. Anticoagulated (10 U heparin/ml blood) venous blood from Macaca fascicularis primates was used and neutrophils were obtained using a modified method ofCraddock et al. (6) . Our modification utilized phosphate-buffered saline with 0.1% glucose (PBSG) rather than Hanks' balanced salt solution with albumin.
Plasma was prepared by incubating 0.4 ml of plasma with 20 M1 of 2 mg/ml endotoxin (E. coli J96) at 37°C for 30 min and at 56°C for 30 min. Plasma was rendered particulate-free by centrifuging at 5,000 g for 10 min after the incubation with endotoxin. Aggregation of neutrophils was determined by aggregometry of neutrophils (5 X 106 cells/ml of PBSG) in an aggregometer (PAP 4, Bio/Data Corp., Willow Grove, PA).
The stimuli for aggregation were: (a) endotoxin activated plasma, (b) endotoxin activated plasma incubated for 15 min with nonspecific rabbit spective stimulus to 250 Ml of neutrophil suspension. All studies reported were performed in triplicate.
Animal preparation. 12 adult male Macaca fascicularis primates (cynomolgus) weighing 4.8-7.2 kg were used in the study (Table I) (16) . Stock cultures were stored in Luria broth with 10% glycerol at -70°C. Stock cultures were innoculated onto trypticase soy agar (TSA) plates and incubated at 37°C for 18 h. The 18-h TSA cultures were harvested into normal saline using sterile fiberfree dacron swabs. The number of colony forming units (CFU) per milliliter of normal saline was determined by construction ofstandard curves by comparing the optical density at 620 nm (1-cm light path) to the number of CFU of serially diluted cuitures by the agar pour technique.
The J96 CFU standard curves were reproducible as determined by identical curves on three different occasions that were each performed in triplicate. The stock intravenous bacteria inoculum was 2.0 X 109 bacteria/ml of saline. This inoculum represented a point on the CFUoptical density standard curve that was on the straight portion of the curve and was randomly checked and confirmed by culture techniques on four different occasions in duplicate during the course of the experiment.
Experimental protocol. Animals were separated into three experimental groups. Group I (n = 4) were control animals to receive 5 mg pooled IgG from nonimmunized rabbits (sham IgG) and 5 ml/kg of sterile saline as a mock E. coli infusion. Group II (n = 4) were septic animals to receive 5 mg sham rabbit IgG and 5 ml/kg of the E. coli suspension (1 X 10'0/kg). Group III (n = 4) were septic animals to receive 5 mg of rabbit anti-human C5a des arg and 5 ml/kg of the E. coli suspension.
After the completion of line placement a pulmonary capillary wedge pressure (PCWP) was measured. If the PCWP was <5 mmHg, fluid was administered according to a predetermined protocol to bring the PCWP to 5 mmHg. Throughout the experiment the fluid resuscitation protocol was used to maintain the PCWP at 5 mmHg.
The fluid resuscitation protocol consisted of normal saline (N/S) administered intravenously to maintain the PCWP at 5 mmHg. PCWP measurement was performed at a minimum interval of 0.2 h. If the PCWP was <5 mmHg, 20 ml of N/S was administered over I min. A PCWP measurement was performed immediately after completion of the bolus. If.the PCWP equaled 5 mmHg, no additional fluid was administered. Ifthe PCWP was <5 mmHg, 40 ml ofN/S was administered over I min and a PCWP measurement was performed. This sequence was repeated until the PCWP equaled 5 mmHg. The pulmonary artery diastolic pressure was evaluated during the infusion of N/S. If the pulmonary artery diastolic pressure had an increase >3 mmHg, the fluid administration was stopped and a PCWP measurement was performed.
Ifthe PCWP was <5 mmHg, the fluid bolus was completed; ifthe PCWP equaled 5 mmHg, no additional fluid was administered.
Baseline data was obtained when the PCWP was 5 mmHg. Data included heart rate; systolic, diastolic, and mean arterial pressure (MAP); systolic, diastolic, and mean pulmonary arterial pressure (PAP); pulmonary capillary wedge pressure (PCWP); central venous pressure; thermal dilution cardiac output; arterial blood gases; and circulating peripheral neutrophil number.
Immediately after baseline data was obtained, antibody infusion was initiated. 5 mg of sham or anti-CSa antibody was diluted in 40 ml N/S and one-third of the solution was infused as a bolus over 1 min. The remaining antibody was infused over 20 min using a Harvard infusion pump (Fig. 1) .
In groups II and III, E. coli infusion (1 X 1010 E. coli/kg) was initiated 5 min after the initiation of the bolus antibody infusion and continued at a constant rate for 30 min using a Harvard infusion pump (Fig. 1) . The end ofthe E. coli infusion was designated time zero and the protocol was carried out for 4 h. Animals that survived the 4 h protocol were killed at 4.2 h.
Arterial blood samples were collected every hour anaerobically and Po2, Pco2, and pH were measured using a Corning blood gas analyzer (Model 178, Corning Medical, Corning Glass Works, Medfield, MA). The alveolar-to-arterial oxygen difference (AaDO2) was calculated (as- Bacterial counts in blood. At 2.5 h a 2-ml blood sample was withdrawn from the femoral arterial line. Samples were obtained from two animals in group I, three animals from group II, and three animals from group III. The vial contained sterile heparin and was immediately processed to determine the number of CFU in the blood. An aliquot was lysed in sterile water and calibrated loops were used to inoculate MacConkey, blood, and trypticase soy agar plates. The plates were incubated at 37°C overnight and read the next day for growth. Positive cultures were gramstained, assessed for hemolysin, and assessed for slide agglutination using anti-J96 0 antigen serum, as described elsewhere (17) . Normal rabbit anti-sera was used as a negative control in the slide agglutination assay.
Gravimetric analysis. At the completion ofthe 4-h experimental protocol (or at death) 10,000 U of sodium heparin was injected into a central venous line. After 5 min, 250 meq of potassium chloride was injected intravenously and the endotracheal tube was clamped. At death a median sternotomy was performed. The lung hila were clamped and the lungs were excised. Gravimetric analysis was done using the method described in detail by Mihm et al. (18) . Extravascular lung water (EVLW) was calculated and reported as milliliters per kilogram body weight.
Statistics. Comparisons were made between groups using the nonparametric Wilcoxon-signed rank test (19 (Fig. 1) . Group II animals died at 105, 150, and 180 min from cardiac arrhythmias and cardiovascular collapse (Fig. 1) . The animals that died at 150 and 180 min also had florid pulmonary edema seen in the endotracheal tube. The fourth animal in group II survived the experimental protocol and had a MAP of 35 mmHg at 4 h (Table I) . In contrast, all control animals (group I) and all animals treated with anti-C5a antibodies (group III) survived for 4 h and were then killed.
All primates receiving E. coli developed septic shock manifested by hypotension, tachycardia, and decreased systemic vascular resistance (SVR) ( Table I, Fig. I ). All group III primates survived and had a significant recovery in their MAP beginning at 105 min (P < 0.05). There was no significant difference between groups I, II, and III in mean PAP, PCWP, or cardiac output.
Septic primates in group II had significantly greater net fluid intake, 52+17 ml/kg per h, than group I, 9±8 ml/kg per h, or group III, 23±1 1 ml/kg per h. There was no significant difference in net fluid intake between groups I and III. Pulmonary injury. Pulmonary injury was assessed by analyzing AaDO2 and EVLW. Baseline AaDO2 results were not significantly different between groups I, II, and III (Fig. 2 A) mmHg, or anti-C5a antibody (group III) treated primates, 20± 10 mmHg (Fig. 2) . EVLW results demonstrated significantly increased lung water (P < 0.05) in the septic primates (group II), 5.0±1.1 ml/ kg, as compared with controls, 1.7±0.3 ml/kg, or anti-C5a antibody treated primates, 2.6±0.4 ml/kg (Fig. 2 B) . There was no significant difference in EVLW between groups I and III (Fig.  2 B) .
Peripheral circulating neutrophils. Peripheral neutrophil counts revealed a significant (P < 0.05) and sustained neutropenia in group II and III animals when compared to group I (Table I) . There was no difference in circulating peripheral neutrophil counts between animals in groups II and III. Neutrophil counts before infusion of anti-CSa antibody or E. coli were 13.6 X 103/mm3±4. 1 (group I), 11.6 X 103/mm3+5.2 (group II), and 12.2 X 103/mm3±7.0 (group III). The sustained neutropenia identified in Table I occurred 15 min before the end of the E. coli infusion, which is noted as time zero. The extent of neutropenia was equal in the septic group (group II) and the septictreated group (group III). 60 min after the end of the E. coli infusion there continued to be no significant difference between group II and group III primates. The neutrophil counts were as follows: 10.9 X 103/mm3±2.5 (control), 2.4 X 103/mm3±2.1 (septic), and 2.7 X 103/mm3+ 1.1 (septic-treated).
Bacterial counts in blood. Bacterial counts were obtained in most but not all animals at 2.5 h. Two septic control animals expired before 2.5 h. Bacterial growth was not detected on any of the plates incubated with samples obtained from group I or control primates (n = 3). In contrast, group II or septic-control primates at 2.5 h had an average bacterial count of 3.9 X I04 CFU/ml of blood ±0.4 (SD) (n = 2). Group III or septic-treated primates at 2.5 h had an average bacterial count of 3.1 X 104 CFU/ml of blood ± 1.5 (SD) (n = 4). There was no difference between groups II and III. All cultures revealed gram-negative organisms that had uniform colony morphology on the plates, uniform and hemolytic colonies on blood agar, and uniform positive lactose fermenting colonies on MacConkey agar. Furthermore, the colonies were agglutinated only by anti-96 0 antisera. From these data, it is evident that all monkeys administered intravenous E. coli J96 had a pure bacteremia due to this organism.
Discussion
This study was designed to determine if rabbit anti-human polyclonal CSa des arg IgG antibodies could prevent C5a-mediated leukocyte aggregation in vitro in primates and ifso, could the anti-GSa antibody attenuate ARDS. Several investigators have demonstrated that CSa is a critical component in the pathogenesis of ARDS (4) (5) (6) . Specifically, respiratory failure in sepsis is considered to be a consequence of GSa-mediated leukocyte attraction, aggregation, activation, and subsequent pulmonary endothelial damage (3). Therefore, ifanti-C5a antibody can functionally block the leukocyte-activating effects of CSa, it is possible that the pulmonary response of primates to live E. coli could be altered.
The results of the present study suggest that anti-CSa antibodies significantly attenuate CSa-mediated leukocyte aggregation in vitro and the respiratory and hemodynamic effects of sepsis in the primate Macaca fascicularis. The septic model produced in this study was acute and severe. The septic animals in group II had ARDS, as indicated by a significant increase in AaDO2 and EVLW (Fig. 2) . Ofinterest is the high early mortality in group II animals. These observations demonstrate that the infusion of 1 X 1010 E. coli/kg is a considerable pulmonary and cardiovascular insult. This infusion of E. coli maintained a marked level of bacteremia that was not different in groups II or III. This demonstrates that anti-C5a did not decrease the degree of bacteremia.
Treatment with anti-C5a antibodies provided significant attenuation of the acute effects of sepsis in group III primates. Survival, pulmonary gas exchange, EVLW, and MAP were all significantly better in these animals. Animals treated with antiC5a antibodies also required significantly less fluid resuscitation to maintain similar PCWP pressures than septic animals in group II. The explanation for this finding could be twofold: first, the antibody therapy decreased capillary leak in the pulmonary and systemic vascular beds, and/or, second, improved pulmonary function minimized the added injury of hypoxemia to the cardiovascular insult. It is important to emphasize that fluid was administered only in response to a PCWP < 5 mmHg in all experimental groups adhering to a strict protocol. In order to maintain adequate intravascular volume, fluid resuscitation requirements differed from group to group. The septic primates without anti-C5a antibodies had the largest fluid requirement (52±17 ml/kg per h) and this increase in fluid in all likelihood contributed to pulmonary edema, hypoxemia, respiratory failure, and death. Thus, it appeared that capillary leak was greatest in the septic primates (group II).
Treatment with anti-C5a antibodies did not prevent a severe and sustained leukopenia that occurred in all the bacteremic animals. This result raises questions regarding the role of neutrophil migration and margination in septic respiratory failure. It seems probable that the sustained neutropenia in group III animals is a consequence of neutrophils marginating either completely systemically or possibly in the lungs without causing as much injury.
The choice of the most appropriate antibody control in this study was difficult. We decided upon pooled rabbit IgG instead of using an antibody against a specific plasma protein even though it has been reported that nonspecific antigen-antibody complexes render neutrophils less responsive, as demonstrated by in vitro phagocytosis assays (20) . However, the possibility still exists that anti-CSa antibody-antigen complexes might have had a nonspecific deleterious effect on neutrophil function, thereby lessening neutrophil-mediated injury.
In our model we believe this possibility is quite unlikely for several reasons. First, anti-C5a antibody was less than 10% of the total IgG infused. Thus, the overwhelming majority of the treatment IgG antibody was rabbit IgG similar to the pooled IgG infused in the septic controls. Second, only one-quarter of the total antibody was infused just 5 min before the bacterial infusion was begun. This short time span made it highly unlikely that neutrophils would be less responsive when the bacterial infusion was begun. The remainder ofthe antibody was infused while the bacterial infusion was being administered. Third, it is important to point out that circulating CSa levels are quite low before the initiation of sepsis; thus, antigen-antibody complex levels should have been low. And fourth, at the conclusion of the bacterial infusion and shortly thereafter, both MAP and peripheral neutrophil count began to fall equally in both the septiccontrol (group II) and septic-treated (group III) primates.
In summary, this study utilizing a severe sepsis model over 
